Under the terms of the agreement, CSL is responsible for the development of protein and antibody products resulting from this alliance. Financial terms of the agreement were not disclosed.
Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.
Ronald Brus, CEO of Crucell, said: “CSL’s expertise in the area of drug development and its proven track record of marketed products offer a good match for our PER.C6 production technology. This alliance is another example of how we can combine our technology with the discoveries brought forth by other biopharmaceutical discovery companies to advance the development of therapeutic products.”